Osimertinib Re-challenge for EGFR-mutant NSCLC after Osimertinib-induced Interstitial Lung Disease: A Case Report
Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with o...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | article |
| Lenguaje: | ZH |
| Publicado: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/08ac61b7c38540368ddbabbcc8b08745 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:08ac61b7c38540368ddbabbcc8b08745 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:08ac61b7c38540368ddbabbcc8b087452021-11-19T06:49:15ZOsimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report1009-34191999-618710.3779/j.issn.1009-3419.2021.102.39https://doaj.org/article/08ac61b7c38540368ddbabbcc8b087452021-11-01T00:00:00Zhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.39https://doaj.org/toc/1009-3419https://doaj.org/toc/1999-6187Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with osimertinib 80 mg/d for first-line targeted therapy. On day 60 after initiating treatment of osimertinib, the patient developed ILD. Osimertinib was discontinued immediately and oral prednisone 60 mg/d was initiated, ILD improved within 13 d. After balancing the risk and benefit, osimertinib was restarted concurrently with prednisone. The patient showed neither disease progression nor a recurrence of ILD for more than 16 months. Based on our case and literature review, retreatment with osimertinib under steroid coverage could be considered as an effective treatment option after careful risk-benefit assessment for patients with EGFR-mutant NSCLC.Junjie GUFan BAILan SONGYingyi WANGChinese Anti-Cancer Association; Chinese Antituberculosis Associationarticleepidermal growth factor receptorinterstitial lung diseaselung neoplasmsosimertinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ZHChinese Journal of Lung Cancer, Vol 24, Iss 11, Pp 804-807 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
ZH |
| topic |
epidermal growth factor receptor interstitial lung disease lung neoplasms osimertinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
| spellingShingle |
epidermal growth factor receptor interstitial lung disease lung neoplasms osimertinib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Junjie GU Fan BAI Lan SONG Yingyi WANG Osimertinib Re-challenge for EGFR-mutant NSCLC after Osimertinib-induced Interstitial Lung Disease: A Case Report |
| description |
Osimertinib-induced interstitial lung disease (ILD) is an uncommon, but fatal pulmonary toxicity in some patients. We report a case of a 64-year-old male with stage IV adeno-non-small cell lung cancer (NSCLC) harboring an exon 19 deletion in the epidermal growth factor receptor (EGFR) treated with osimertinib 80 mg/d for first-line targeted therapy. On day 60 after initiating treatment of osimertinib, the patient developed ILD. Osimertinib was discontinued immediately and oral prednisone 60 mg/d was initiated, ILD improved within 13 d. After balancing the risk and benefit, osimertinib was restarted concurrently with prednisone. The patient showed neither disease progression nor a recurrence of ILD for more than 16 months. Based on our case and literature review, retreatment with osimertinib under steroid coverage could be considered as an effective treatment option after careful risk-benefit assessment for patients with EGFR-mutant NSCLC. |
| format |
article |
| author |
Junjie GU Fan BAI Lan SONG Yingyi WANG |
| author_facet |
Junjie GU Fan BAI Lan SONG Yingyi WANG |
| author_sort |
Junjie GU |
| title |
Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report |
| title_short |
Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report |
| title_full |
Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report |
| title_fullStr |
Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report |
| title_full_unstemmed |
Osimertinib Re-challenge for EGFR-mutant NSCLC after
Osimertinib-induced Interstitial Lung Disease: A Case Report |
| title_sort |
osimertinib re-challenge for egfr-mutant nsclc after
osimertinib-induced interstitial lung disease: a case report |
| publisher |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| publishDate |
2021 |
| url |
https://doaj.org/article/08ac61b7c38540368ddbabbcc8b08745 |
| work_keys_str_mv |
AT junjiegu osimertinibrechallengeforegfrmutantnsclcafterosimertinibinducedinterstitiallungdiseaseacasereport AT fanbai osimertinibrechallengeforegfrmutantnsclcafterosimertinibinducedinterstitiallungdiseaseacasereport AT lansong osimertinibrechallengeforegfrmutantnsclcafterosimertinibinducedinterstitiallungdiseaseacasereport AT yingyiwang osimertinibrechallengeforegfrmutantnsclcafterosimertinibinducedinterstitiallungdiseaseacasereport |
| _version_ |
1718420295089389568 |